Find companies by what is true of them right now — the grade from their filings, the share price and how far it sits below its 52-week high, what it costs, what it pays and whether it lists options. Start from a named screen and adjust it.
Graded F at each of the last four quarter ends and still F today: failing most of the growth-and-cash checks for a year. The grade describes the filings, not the price, and says nothing about what the shares will do.
33 companies match
| Company | Grade | Run | Price | Below high | P/E | Size | Yield | Options | Industry |
|---|---|---|---|---|---|---|---|---|---|
| VKTXViking Therapeutics, Inc. | F | 29 quarterssince Jun 2019 | $35.56 | -16% | — | $4.1B | — | Weekly | Biotechnology |
| RVMDRevolution Medicines, Inc. | F | 22 quarterssince Mar 2021 | $204.97 | -7% | — | $43.9B | — | Monthly | Biotechnology |
| F | 17 quarterssince Jun 2022 | $6.56 | -28% | — | $1.7B | — | Monthly | Oil Gas Equipment and Services | |
| F | 16 quarterssince Sep 2022 | $85.69 | -21% | — | $7.6B | — | Monthly | Biotechnology | |
| F | 15 quarterssince Dec 2022 | $36.94 | -48% | — | $3.6B | — | Monthly | Biotechnology | |
| F | 12 quarterssince Sep 2023 | $15.61 | -41% | — | $12.5B | — | Weekly | Biotechnology | |
| F- | 12 quarterssince Sep 2023 | $3.57 | -37% | — | $2.1B | — | Weekly | Reit Healthcare Facilities | |
| F- | 11 quarterssince Dec 2023 | $1.64 | -5% | — | $1.2B | — | Monthly | Diagnostics and Research | |
| F- | 10 quarterssince Mar 2024 | $20.39 | -25% | — | $3.3B | — | Monthly | Biotechnology | |
| F | 10 quarterssince Mar 2024 | $21.41 | -28% | — | $2.4B | — | Monthly | Biotechnology | |
| F | 9 quarterssince Jun 2024 | $56.95 | -37% | 6.07 | $4.3B | 2.0% | Monthly | Steel | |
| F | 8 quarterssince Sep 2024 | $36.87 | -25% | 75.24 | $87.3B | 0.7% | Monthly | Asset Management | |
| F | 8 quarterssince Sep 2024 | $20.01 | -24% | 30.32 | $14.4B | 4.2% | Monthly | Reit Specialty | |
| F- | 8 quarterssince Sep 2024 | $7.75 | -2% | — | $2.8B | — | Monthly | Biotechnology | |
| F- | 7 quarterssince Dec 2024 | $28.02 | -32% | — | $20.2B | 5.0% | Weekly | Chemicals | |
| F | 7 quarterssince Dec 2024 | $36.89 | -19% | 32.08 | $3.8B | 6.4% | Monthly | Staffing and Employment Services | |
| F- | 6 quarterssince Mar 2025 | $4.60 | -62% | — | $13.3B | — | Weekly | Auto Manufacturers | |
| F | 6 quarterssince Mar 2025 | $15.25 | -4% | — | $10.4B | — | Monthly | Medical Instruments and Supplies | |
| F- | 6 quarterssince Mar 2025 | $22.64 | -14% | — | $6.4B | 3.0% | Monthly | Reit Retail | |
| F | 5 quarterssince Jun 2025 | $53.84 | -0% | — | $14.7B | 2.1% | Monthly | Asset Management | |
| F- | 5 quarterssince Jun 2025 | $49.93 | -38% | — | $8.7B | 7.0% | Monthly | Reit Office | |
| F | 5 quarterssince Jun 2025 | $280.78 | -27% | — | $7.8B | — | Monthly | Biotechnology | |
| F | 5 quarterssince Jun 2025 | $17.34 | -41% | — | $5.6B | — | Weekly | Software Infrastructure | |
| F | 5 quarterssince Jun 2025 | $66.70 | -32% | 85.51 | $4.7B | 1.8% | Monthly | Building Products and Equipment | |
| F | 5 quarterssince Jun 2025 | $21.33 | -18% | 12.21 | $2.5B | 3.0% | Monthly | Internet Content and Information | |
| F- | 5 quarterssince Jun 2025 | $26.95 | -38% | — | $1.8B | — | Monthly | Biotechnology | |
| F | 4 quarterssince Sep 2025 | $11.61 | -55% | — | $3.4B | — | Monthly | Metal Fabrication | |
| F- | 4 quarterssince Sep 2025 | $16.47 | -10% | — | $2.7B | — | Monthly | Oil Gas E and P | |
| F- | 4 quarterssince Sep 2025 | $41.73 | -33% | 57.16 | $2.5B | 2.4% | Weekly | Auto Parts | |
| F- | 4 quarterssince Sep 2025 | $31.10 | -31% | — | $2.4B | — | Monthly | Biotechnology | |
| F- | 4 quarterssince Sep 2025 | $57.94 | -48% | — | $2.2B | — | Monthly | Semiconductor Equipment and Materials | |
| F- | 4 quarterssince Sep 2025 | $31.71 | -65% | 10.82 | $2.1B | 14.0% | Monthly | Furnishings Fixtures and Appliances | |
| F- | 4 quarterssince Sep 2025 | $9.74 | -16% | — | $1.7B | — | Monthly | Biotechnology |
A screen is a filter, not a recommendation. Every row met the stated test and nothing more — InspectStocks describes businesses from their own SEC filings and does not advise buying or selling anything.